Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.42 |
| ▸ | NPY1R | P25929 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788898 | 0.89 | CRHR1 (0.48) | CRHR1NPY1RL3MBTL1ALDH1A1MAPT | |
| SCHEMBL7783161 | 0.84 | CRHR1 (0.54) | CRHR1NPY1RPOLBKDM4E | |
| SCHEMBL7684159 | 0.77 | CRHR1 (0.44) | CRHR1ALDH1A1KDM4E | |
| SCHEMBL7788172 | 0.76 | CRHR1 (0.46) | CRHR1NPY1RPOLBALDH1A1KDM4E | |
| SCHEMBL7788921 | 0.75 | CRHR1 (0.49) | CRHR1ALDH1A1KDM4E | |
| SCHEMBL7788903 | 0.74 | CRHR1 (0.49) | CRHR1POLBALDH1A1MAPTKDM4E | |
| SCHEMBL7791098 | 0.74 | CRHR1 (0.47) | CRHR1ALDH1A1MAPTKDM4E | |
| SCHEMBL7783159 | 0.74 | CRHR1 (0.53) | CRHR1ALDH1A1 | |
| SCHEMBL7674366 | 0.73 | CRHR1 (0.40) | CRHR1NPY1RALDH1A1MAPTKDM4E | |
| SCHEMBL7675196 | 0.73 | CRHR1 (0.40) | CRHR1NPY1RALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NEUROGEN CORPORATION | 2001-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NPY1R, NPY2R, NPY5R | CRHR1 33/4885NPY1R 1/4885L3MBTL1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.